Treatment with target-specific direct oral anticoagulants (DOACs) after transcatheter mitral valve replacement (TMVR) is associated with a lower risk of bleeding than anticoagulation with vitamin K antagonists (VKAs), without a significant increase in the risk of thrombotic events, new patient data suggest.